HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Sequentially alternating chemotherapy of non-seminomatous testicular tumors with adriamycin/cisplatin and bleomycin/vinblastine. Therapeutic success and failure with respect to histology and tumor stages].

Abstract
The value of sequential alternating chemotherapy was analyzed retrospectively in 180 patients with disseminated, non-seminomatous testicular cancer. Response rates of adriamycin/cisplatin--(combination A) and bleomycin/vinblastine (combination B)--combination chemotherapy were evaluated separately with respect to tumor histology and tumor stages. Tumor response was achieved in 151 of 180 patients (84%) who were evaluable for adriamycin/cisplatin chemotherapy. Out of those, 91 of 117 patients (78%) pretreated with combination B and 60 of 63 patients (95%) without prior chemotherapy responded. Irrespective of pretreatment tumor response was observed in 131 of 157 patients (84%) evaluable for treatment with bleomycin/vinblastine. Resistance to combination A was 2.5 fold higher in embryonal carcinomas (class II of Dixon and Moore) than in choriocarcinomas (class V). Bleomycin/vinblastine-therapy failed more frequently in choriocarcinomas as compared to other histological categories (22% vs. 14%). This report also includes an analysis of treatment failures in different tumor stages. Both regimens were more frequently ineffective in tumor stages with a large tumor burden (stages II C and IV D). Patterns of cross-resistance were evaluated for both regimens. Response to adriamycin/cisplatin occurred in 18/26 patients (69%), when combination B had failed, and response to bleomycin/vinblastine was achieved in 14/24 patients (58%) when adriamycin/cisplatin had failed. In patients not responding to either regimen the treatment failure was already recognized after the first chemotherapeutic course in 93% of these cases.
AuthorsJ Schütte, K Bremer, N Niederle, B Schoetensack, C G Schmidt, S Seeber
JournalOnkologie (Onkologie) Vol. 6 Issue 1 Pg. 16-20 (Feb 1983) ISSN: 0378-584X [Print] Switzerland
Vernacular TitleSequentiell-alternierende Chemotherapie nicht-seminomatöser Hoden-tumoren mit Adriamycin/Cisplatin und Bleomycin/Vinblastin. Therapieansprechen und -versagen in Abhängigkeit von Histologie und Tumorstadium.
PMID6189038 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Bleomycin
  • Vinblastine
  • Doxorubicin
  • Cisplatin
Topics
  • Antineoplastic Agents (administration & dosage)
  • Bleomycin (administration & dosage)
  • Cisplatin (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Drug Resistance
  • Drug Therapy, Combination
  • Humans
  • Male
  • Neoplasm Staging
  • Retrospective Studies
  • Testicular Neoplasms (drug therapy, pathology)
  • Vinblastine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: